| Literature DB >> 34822542 |
Marta Justyna Kozieł1, Maksymilian Ziaja1, Agnieszka Wanda Piastowska-Ciesielska1.
Abstract
The intestinal barrier is the main barrier against all of the substances that enter the body. Proper functioning of this barrier guarantees maintained balance in the organism. Mycotoxins are toxic, secondary fungi metabolites, that have a negative impact both on human and animal health. It was postulated that various mycotoxins may affect homeostasis by disturbing the intestinal barrier. Claudins are proteins that are involved in creating tight junctions between epithelial cells. A growing body of evidence underlines their role in molecular response to mycotoxin-induced cytotoxicity. This review summarizes the information connected with claudins, their association with an intestinal barrier, physiological conditions in general, and with gastrointestinal cancers. Moreover, this review also includes information about the changes in claudin expression upon exposition to various mycotoxins.Entities:
Keywords: claudins; intestinal barrier; mycotoxins; tight junctions
Mesh:
Substances:
Year: 2021 PMID: 34822542 PMCID: PMC8622050 DOI: 10.3390/toxins13110758
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Diagram showing the intestinal barrier components. The graphical illustration was prepared by using the images from Servier Medical Art by Servier. Minor modifications were made (e.g., color of the stock images, some shapes) (https://smart.servier.com/smart_image/, accessed on 19 July 2021).
Claudins expression in various parts of the gastrointestinal tract (GI) in mammals. * Distinguished parts of the colon.
| Part of GI Tract | Claudins | References | |||
|---|---|---|---|---|---|
| Human | Mouse | Rat | Pig | ||
| Mouth | 1, 4, 7, 8, 17 | 1, 2, 3, 4, 6, 7, 10, 11, 12, 17, 18, 23 | - | 4, 7 | [ |
| Esophagus | 2, 3, 4, 7, 8, 12, 15, 18 | - | - | - | [ |
| Stomach | 10, 11, 14, 17, 18, 23 | 1, 3, 5, 6, 11, 18 | - | 1 | [ |
| Duodenum | 1, 2, 3, 4, 7, 8, 12, 15, 18 | 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14, 15, 18 | 1, 2, 3, 4, 5, 7, 8, 12 | 1, 3, 4, 5 | [ |
| Jejunum | 2 | 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18 | 1, 2, 3, 5, 7, 12 | 1, 3, 4, 5 | [ |
| Ileum | 2, 3, 4, 7, 8, 12, 15, 18 | 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15 | 1, 2, 3, 5, 7, 8, 12 | 1, 3, 4, 5 | [ |
| Cecum | - | 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14, 15 | - | - | [ |
| Colon | - | 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14, 15 | 1, 2, 3, 4, 5, 7, 8, 9, 12 | 1, 4 | [ |
| 2, 3, 4, 7, 8, 12, 15, 18 | - | - | - | [ | |
| 2, 3, 4, 7, 8, 12, 15, 18 | - | - | - | [ | |
| 2, 3, 4, 7, 8, 12, 15, 18 | - | - | - | [ | |
| 2, 3, 4, 7, 8, 12, 15, 18 | - | - | - | [ | |
| rectum | 1, 2, 3, 4, 7, 8, 12, 15, 18 | - | 3 | - | [ |
Figure 2Diagram showing the consequences of abnormal claudin expression. EMT—epithelial to mesenchymal transition.
Summarized information about claudin proteins expression in GI cancer cell line. ↑—up-regulated, ↓—downregulated.
| Cancer | Claudin | Expression | Described Effects on Cells | References |
|---|---|---|---|---|
| Oral | 1 | ↑ | Invasiveness ↑ | [ |
| 7 | ↓ | Invasiveness ↑ | [ | |
| Oesophageal | 1 | ↑ | Proliferation ↑ | [ |
| 4 | ↓ | Growth ↑ | [ | |
| 7 | ↓ | Invasiveness ↑ | [ | |
| Liver | 1 | ↓ | Invasiveness ↑ | [ |
| 3 | ↓ | Invasiveness ↑ | [ | |
| 10 | ↑ | Angiogenesis ↑ | [ | |
| Gastric | 1 | ↑ | Apoptosis ↑ | [ |
| 4 | ↑ | Invasiveness ↑ | [ | |
| 4 | ↓ | Migration ↑ | [ | |
| 6 | ↑ | Migration ↑ | [ | |
| 7 | ↑ | Migration ↑ | [ | |
| 9 | ↑ | Migration ↑ | [ | |
| 11 | ↓ | Migration ↑ | [ | |
| Colorectal | 1 | ↑ | Growth ↑ | [ |
| 2 | ↑ | Colony formation ↑ | [ | |
| 3 | ↓ | Proliferation ↑ | [ | |
| 7 | ↓ | EMT ↑ | [ |
Total tolerable daily intake present for mycotoxins described in this review based on EFSA reports.
| Mycotoxin | Total Tolerable Daily Intake | References |
|---|---|---|
| Aflatoxins | Not established | - |
| Fumonisin B1 | 1 µg/kg | [ |
| Zearalenone | 0.25 µg/kg | [ |
| Deoxynivalenol | 1 µg/kg | [ |
| Patulin | Not established | - |
Figure 3Mycotoxins and their influence on intestinal physiology. DON—deoxynivalenol, PAT—patulin, ZEA—Zearalenone, FB1—Fumosin B1, AFB1—Aflatoxin B1.
Summarized information about mycotoxins and their relationship to claudins in colon cancer cell lines. * only markedly affected, but distribution was disturbed, ↓ lower value/expression, AFM1—aflatoxin M1, ZEA—zearalenon, OTA—ochratoxin A, AFB1—aflatoxin B1.
| Mycotoxin | Cell Line | TEER Values | Targeted Claudin | References |
|---|---|---|---|---|
| Aflatoxin B1 | Caco-2 | ↓ | [ | |
| Ochratoxin A | Caco-2, HT-29-DR | ↓ | [ | |
| Patulin | Caco-2 | ↓ | [ | |
| T-2 toxin | Caco-2 | ↓ | [ | |
| Fumonisin B1 | Caco-2 | ↓ | [ | |
| Deoxynivalenol | Caco-2, T84, HT-29-DR | ↓ | [ | |
| AFM1 + ZEA + OTA (combination) | Caco-2 | ↓ | [ | |
| AFM1 + OTA | Caco-2 | ↓ | [ | |
| AFM1 + AFB1 | Caco-2 | ↓ |
| [ |